Please provide positive comments to each paragraph below, independently. Thanks
1-PMHNPs can stay current with advancements in this rapidly evolving field by attending conferences, workshops, and continuing education courses focused on Alzheimer’s disease and biomarkers. Keeping up with the latest research publications and guidelines from organizations such as the Alzheimer’s Association and the National Institute on Aging can also help PMHNPs stay informed about new developments in the field.
In conclusion, managing treatment-resistant schizophrenia and utilizing biomarkers for Alzheimer’s disease require a comprehensive and personalized approach to care. By staying current with advancements in these fields, PMHNPs can provide the best possible care for their patients
2- Management of treatment-resistant schizophrenia, as an PMHNP, I would approach in three ways. First, I would re-evaluate the case to ensure accuracy. Here, I would determine whether the patient is currently adhering to the set treatment protocols and review medication compliance. Second, I would review the patient’s engagement in substance use and/or recreational drugs and maybe even consider genetic testing to see which medication may work best (and have fewer side effects) based on their genetic make up and/or chromosomal variations. After ascertaining that the patient adheres to their treatment protocol, I would prescribe clozapine, the main drug used for managing treatment-resistant schizophrenia (Farooq et al., 2019) along with baseline absolute neutrophil count (ANC) and white blood cell (WBC) count. Third, I would review the patient’s social support systems such as housing and address any related concerns and make sure to incorporate therapy into their treatment plan.
